Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

Common GLP-1 weight loss drugs - including Wegovy and Ozempic - may not work for everyone in a “real-world” setting, ...

In the real world, the use of semaglutide (Wegovy) and tirzepatide (Zepbound) produce far less ... which confirms the efficacy of this medications for the prevention of type 2 diabetes but also ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

Semaglutide (sold under the brand names Wegovy and Ozempic) and tirzepatide (sold under the brand names Zepbound and Mounjaro ... (glycemic control) in a real-world setting.

The SURMOUNT-5 trial, a Phase 3b open-label clinical trial, examined the safety and efficacy of ... “In real-world terms, that means many patients on Zepbound are losing more weight than those ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. The randomized, controlled trial — called ...

In an emailed statement to CBS News Monday, a spokesperson for Novo Nordisk, the maker of Wegovy and Ozempic, said both Wegovy and Zepbound have ... disease backed by real-world evidence." ...

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50 percent ... out in what Aronne said many view as “a drag race of efficacy,” both are important tools for treating obesity ...

Eli Lilly said its Zepbound obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy will have the option to buy now and pay later under a partnership announced Tuesday by ...